# An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

> **NCT03583372** · PHASE3 · COMPLETED · sponsor: **Urovant Sciences GmbH** · enrollment: 506 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Vibegron
- **DRUG:** placebos
- **DRUG:** Tolterodine Tartrate ER

## Key facts

- **NCT ID:** NCT03583372
- **Lead sponsor:** Urovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-14
- **Primary completion:** 2019-06-13
- **Final completion:** 2019-07-25
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583372, "An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03583372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*